초록

* 동물모델에서 백신 투여 방법에 따른 면역반응 비교 및 최적의 투여 방법, 투여량 확립.
* 점막투과 및 점착 특성을 갖는 점막 면역 유도 백신 전달체의 개발 및 특성 확인
* 동물 모델에서 백신 투여에 의한 세포성 체액성 면역 반응 유도 및 작용기작 규명
* 동물모델에서 백신의 안전성 및 효능성 검증을 통한 최적화된 백신개발
* 최종적으로 도출된 나노 전달시스템 기술을 이용하여 현재 많은 주목을 받고 있는 면역치료나 면역세포를 이용한 치료제 개발 기술의 토대 마련 할 수 있도록 활용할 계획임.

Abstract ▼

The design and synthesis of nanomaterials that can modulate the immune system are the hottest issues in the field of immunology-related nanomedicine due to the increasing interest in infectious diseases world-wide. Because most pathogens access the body through mucosal membranes, effective vaccines

The design and synthesis of nanomaterials that can modulate the immune system are the hottest issues in the field of immunology-related nanomedicine due to the increasing interest in infectious diseases world-wide. Because most pathogens access the body through mucosal membranes, effective vaccines that protect these sites are highly needed.There is general agreement that effective mucosal vaccines, including oral, nasal, sublingual and genital tract vaccines, could dramatically contribute to the improvement of global health by stimulating a protective immune response not only against mucosal infections but also against HIV, Mycobacterium tuberculosis and many other infections. Mucosal vaccines are more advantageous than systemic vaccines from a production and regulatory perspective. Specifically, mucosal vaccines are practical for mass vaccination and do not involve the risk of blood-borne infections, which may occur due to contaminated injection needles. The ease of administration, improved compliance and the possibility of delivery by personnel without medical training are also viewed as benefits of mucosal vaccine strategies, especially for preventing the pandemic spread of infections, including influenza virus infections. However, only a few commercially available mucosal vaccines currently exist because of challenges to effective mucosal vaccination, such as difficulties in generating effective mucosal immunity, as well as the lack of safe, effective mucosal adjuvants and delivery systems.Vaccine adjuvants can act in different ways to increase both an innate and adaptive immune response and generate an effective immunological memory. Adjuvants act by prolonging the exposure time of the antigen in the immune system, enhancing the delivery of the antigen to antigen-presenting cells, or providing immunostimulatory signals that potentiate the immune response. Although the mucus vaccine delivery strategy is regarded as a potent needle-free vaccine delivery, the limitations associated with the mucociliary clearance mechanism inhibit the delivery of antigens to the immune system. Accordingly, new approaches for mucus vaccine delivery systems that can improve the antigen passage through biological barriers, such as the intestinal and nasal mucosa, are in high demand because they hold promise for the generation of efficient mucosal immunity using needle-free vaccines.